Glutamate receptors as a target for Alzheimer’s disease — are clinical results supporting the hope?
- 1 January 2002
- book chapter
- Published by Springer Nature
- No. 62,p. 217-225
- https://doi.org/10.1007/978-3-7091-6139-5_20
Abstract
Several years after the introduction of cholinergic drugs in Alzheimer’s disease therapy, other approaches for symptomatic and also disease-modifying pharmacotherapy are progressing in their development. Among these, the NMD A antagonist memantine represents the most advanced and promising agent, gifted with many years of clinical experience in Germany. This paper provides an overview of both, the novel pharmacological background and recent clinical evidence in dementia. Memantine was recently recommended for central European approval.Keywords
This publication has 0 references indexed in Scilit: